Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ADMA

ADMA Biologics, Inc.

Healthcare | Biotechnology
$8.58 +0.08 (+0.94%) as of 2026-07-15 03:57 UTC
Market Cap$2.0B
Volume3.40M
EPS (TTM)$0.60

ADMA Biologics, Inc. (NASDAQ: ADMA) is a $2.0B biotechnology company trading at $8.58 (+0.9% today) — 14.3× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-15 03:57 UTC.

52-Week Range
Low $7.21High $20.97

What ADMA Biologics, Inc. does

ADMA Biologics is a U.S. biopharmaceutical company that manufactures and markets specialty immune globulin products for immunodeficient and immunosuppressed patients. The company currently sells three FDA-approved products: ASCENIV and BIVIGAM for primary immunodeficiency treatment, and Nabi-HB for hepatitis B exposure. ADMA manufactures these products at its FDA-licensed plasma fractionation facility in Boca Raton, Florida, and operates plasma collection centers through its subsidiary ADMA BioCenters to secure raw materials and sell excess plasma to third parties.

Summarized from ADMA Biologics, Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$8.58
Change (1D)+0.08 (+0.94%)
Market cap$2.0B
Volume3.40M shares
52-week range$7.21 – $20.97
Valuation
P/E (TTM)14.30×
EV/EBITDA10.10×
EPS (TTM)$0.60
Price/book4.27×
Return on equity30.78%
Debt/equity0.15
Returns
52-week return+19.0%
Revenue, margins & earnings
FY2021: net loss $72M on revenue $81M$81MFY2021FY2022: net loss $66M on revenue $154M$154MFY2022FY2023: net loss $28M on revenue $258M$258MFY2023FY2024 Revenue: $426M — margin split not shown (non-operating gains)$426MFY2024FY2025 Net income: $147MFY2025 Taxes & interest: $45MFY2025 Operating expenses: $101MFY2025 Cost of revenue: $217M$510MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-05-28
  • 2026-05-28Grossman Jerrold BBUY6,400$50.6K
  • 2026-05-14Grossman Jerrold BBUY12,500$100.1K
  • 2026-05-12Grossman Jerrold BBUY12,500$100.1K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • VANGUARD GROUP INC20,496,224$373.85M-2.3%
  • BlackRock, Inc.26,377,879$237.66M-27.4%
  • Sachem Head Capital Management LP11,375,000$207.48M+26.9%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does ADMA Biologics, Inc. do?

ADMA Biologics, Inc. is a biotechnology company, listed on NASDAQ as ADMA.

What is ADMA's valuation?

ADMA trades at $8.58, 14.30× trailing earnings, 10.10× EV/EBITDA, as of 2026-07-15.

When did ADMA last file with the SEC?

ADMA Biologics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-15 03:57 UTC. This page is also available as JSON at /api/data?ticker=ADMA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ADMA and 3,500+ tickers.

Create a free account — keep ADMA
For your agent
GET /api/data?ticker=ADMA

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt